Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail used in the treatment of Covid-19 Kumar Jeetendra | May 5, 2021 Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19 Casirivimab and Imdevimab is indicated for the treatment of mild to moderate Covid-19 in high-risk patients Partners with Cipla for pan-India distribution At a global level, Roche and its partner Regeneron are collaborating to …
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India Kumar Jeetendra | May 24, 2021 Mumbai, 24 May 2021: Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as …
